biotechnology

We take a look at 4 Pharma & Biotech companies whose share prices rallied in October on the back of positive announcements.

Wilsons Advisory’s Melissa Benson and Shane Storey share their insights in the final part of the biotech mini-series.

KP Rx’s Hashan De Silva thinks so and is seeing enormous opportunities at attractive valuations.

Despite a bear market, this sector has seen innovation accelerate and its fortunes are about to change.

In this episode, Nina shares her background and what it taught her about the challenge of running a biotech firm.

...according to HB Biotechnology’s Charlie Williams.

Advances in healthcare are one of the greatest advantages of the times we live in and it's only getting more exciting (and profitable).

There were some strong moves in the Pharma and Biotech sector in May, with the share prices of 33 companies in the coverage universe rising by 10% or more. Below we...

Uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts.

The rapid pace of change in biotechnology is creating a golden age of innovation - and three experts share what they are watching.

The healthcare sector has made a stunning return after a poor 2023. Three experts share their thoughts on what happened and what to watch.

Platinum's Dr Bianca Ogden shares the big tech trends transforming healthcare and companies she likes

The below takes a look at six ASX pharma and biotech stocks that experienced significant share price moves through the month as important news flow came through. 1)...

Are healthcare stocks "expensive defensives"? And what do brokers, and Wilson Asset Management's Anna Milne, think of the biggest ASX companies in the sector? We find...

It’s hard to pinpoint where it really started: our mass desire for personalised products and services. Was it as early as the ability to monogram handbags? Or pick...

We're entering a new age courtesy of technology. Personalisation and automation is the name of the game and it's going to be life-changing. But with technology...

So far in 2022, the defensive nature of health care has been the sector’s dominant story, with the S&P 500® Health Care sector returning -5.7% for the year compared...

This episode is just such an absolute cracker! We have such an awesome opportunity to spend some time in conversation with a true leader in their field - Life...

Like all good venture capitalists, I started my career in the trenches working on the front line of my target industry, as a molecular biologist at LaTrobe University....

At midnight a couple of days ago the US Food and Drug Administration announced the approval of Biogen's Alzheimer's drug Aducanumab. Usually, when a drug is approved...